Please ensure Javascript is enabled for purposes of website accessibility

Why Nektar Therapeutics Fell 36.5% in October

By Cory Renauer – Nov 7, 2018 at 8:23AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are beginning to think Bristol-Myers Squibb made a bad decision.

What happened

Shares of Nektar Therapeutics (NKTR -2.48%), a commercial-stage biotechnology company, fell 36.5% in October, according to data from S&P Global Market Intelligence. The company didn't release any significant news regarding its lead cancer candidate, NKTR-214, but investors continued lowering their expectations.

So what 

A strong initial response rate among cancer patients treated with a combination of Opdivo from Bristol-Myers Squibb (BMY -0.81%) inspired the big pharma to sign a very lucrative deal for rights to NKTR-214. Results released following the deal, though, have investors wondering if Bristol-Myers made a huge mistake.

Man drawing a downward-sloping chart.

Image source: Getty Images.

Nektar's candidate is a pegylated version of another treatment that was shown to shrink tumors for around 15% of patients who took it. During an earlier study with NKTR-214 as a solo treatment for patients after they've had Opdivo or a similar drug, investigators couldn't confirm a tumor response among any of the 28 patients treated.

Now what

If response rates within the Pivot-2 combination study slide any further, Nektar's big partnership with Bristol-Myers isn't going anywhere. Luckily, Pfizer (PFE -1.10%) recently signed an agreement to test NKTR-214 in combination with Bavencio; Xtandi; and a recently approved PARP inhibitor, Talzenna.

If NKTR-214 is a total bust, the company will survive. Nektar's balance sheet had $1.8 billion in cash and short-term investments at the end of June courtesy of Bristol-Myers Squibb. Product sales and royalty revenue added $32 million to the company's top line in the first half of 2018, which gives a handful of additional new drug candidates in the company's clinical stage pipeline plenty of chances to shine.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nektar Therapeutics Stock Quote
Nektar Therapeutics
$3.14 (-2.48%) $0.08
Pfizer Inc. Stock Quote
Pfizer Inc.
$44.08 (-1.10%) $0.49
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$70.71 (-0.81%) $0.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.